Prometheus dissected: Will chaos rule in patenting?
This article was originally published in Scrip
When the US Supreme Court invalidated diagnostic methods patents held by Prometheus Laboratories in a 20 March decision, John Whealan, associate dean for intellectual property law studies at George Washington Law School, said he found himself in the uncomfortable position of not being able to explain to his students why the justices ruled the way they did and what the decision meant.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.